Type I interferon responses are considered the primary means by which viral infections are controlled in mammals. Despite this view, several pathogens activate antiviral responses in the absence of type I interferons. The mechanisms controlling type I interferon-independent responses are undefined. We found that RIG-I like receptors (RLRs) induce type III interferon expression in a variety of human cell types, and identified factors that differentially regulate expression of type I and type III interferons. We identified peroxisomes as a primary site of initiation of type III interferon expression, and revealed that the process of intestinal epithelial cell differentiation upregulates peroxisome biogenesis and promotes robust type III interferon responses in human cells. These findings highlight the importance of different intracellular organelles in specific innate immune responses. npg
A r t i c l e s In mammals, antiviral responses are classically defined as being mediated by type I interferons. These secreted proteins act via interferon receptors to upregulate interferon-stimulated genes (ISGs) that exhibit diverse antiviral activities 1 . Despite this paradigm, there are several examples of infections that induce expression of ISGs independently of type I interferons [2] [3] [4] [5] . The mechanisms by which these type I interferon-independent activities are induced remain unclear. One such example comes from studies of the signaling events mediated by RLRs 2 . RLRs are RNA helicases that function in virtually all mammalian cells to detect viral and bacterial nucleic acids in the cytosol 6 . The two best-characterized RLRs are RIG-I and Mda5, which differ mainly in their ability to recognize distinct RNA structures. RIG-I detects short double-stranded RNA that contains a 5′ triphosphate group, and Mda5 detects long double-stranded RNA structures 6 . These distinct recognition profiles are thought to explain the importance of each RLR in the detection of different classes of viral pathogens 7 .
Upon detection of viral RNA, RLRs engage an adaptor protein called MAVS (also known as IPS-1, Cardif or VISA) 8 , which is located on the limiting membranes of mitochondria, peroxisomes and mitochondriaassociated membranes of the endoplasmic reticulum 2, 8, 9 . Engagement of MAVS by RLRs activates a signaling cascade that induces numerous antiviral activities 10 . Mitochondria-localized MAVS induces an antiviral response typified by the expression of type I interferons and ISGs. In contrast, RLR signaling via MAVS on peroxisomes does not induce the expression of any type I interferon but does induce expression of ISGs 2 . This atypical antiviral response is functional, as cells expressing MAVS exclusively on peroxisomes restrict the replication of two mammalian RNA viruses, reovirus and vesicular stomatitis virus (VSV). Thus, although it is clear that type I interferonindependent mechanisms of antiviral immunity exist, the regulation of these mechanisms remains largely undefined. This lack of information represents a fundamental gap in our knowledge of the means by which mammalian cells respond to intracellular pathogens.
Here we report that RLR signaling in human cells can induce the expression of type III interferons, a class of interferons that has tissue-specific roles in antiviral immunity 11 . We found that RLRmediated type III interferon expression can be induced by diverse viruses, including reovirus, Sendai virus (SeV) and dengue virus (DenV) as well as the bacterial pathogen Listeria monocytogenes. We identified peroxisomes as signaling organelles that act to induce type III interferon-mediated ISG responses, which complement the actions of the type I interferon responses induced from mitochondria. During the natural process of epithelial cell differentiation and polarization, we observed an increase in the type III interferon response that correlated with abundance of peroxisomes, and cells derived from individuals with peroxisomal disorders displayed aberrant antiviral responses. These data establish the importance of peroxisomes in controlling interferon responses and highlight the interconnectedness of the RLR pathways with the metabolic organelles of mammalian cells.
RESULTS
Jak-STAT-dependent RLR signaling from peroxisomes Type I interferons are neither detected nor required for antiviral responses induced by RLRs from peroxisomes 2 , which suggests a A r t i c l e s cell-intrinsic means of antiviral immunity. Cell-intrinsic responses are considered those that do not involve the actions of secreted factors. To determine whether cellular responses induced from peroxisomes induce the secretion of any antiviral factors, we used previously characterized MAVS-deficient mouse embryonic fibroblasts (MEFs) 2 . These MEFs stably express MAVS transgenes that had been engineered to be localized to specific organelles. The resulting isogenic cell populations only differ in that they display MAVS on mitochondria (MAVS-mito), on peroxisomes (MAVS-pex) or in the cytosol (MAVS-cyto). We infected these cells with mammalian reovirus (a physiological activator of RLRs) and transferred culture supernatants from infected cells onto Huh7.5 human hepatocyte-like cells. Huh7.5 cells are an Huh7 derivative that carries a loss-of-function mutation in RIG-I 12 . We assessed the antiviral activity of the supernatants by monitoring phosphorylation of the transcription factor STAT1. The fact that Huh7.5 cells are deficient for RIG-I signaling ensures that a response would be due to MEF secretion in the supernatant and not carryover virus. Culture supernatants from infected MAVS-pex and MAVS-mito MEFs activated phosphorylation of STAT1 in Huh7.5 cells (Fig. 1a) . In contrast, supernatants from cells expressing the signaling-defective 'MAVS-cyto' allele 2,8 could not trigger phosphorylation of STAT1, which indicated that these supernatants did not contain any STAT1 activators. This finding suggested that peroxisomal MAVS can activate cell-extrinsic antiviral responses, despite its inability to induce type I interferon expression 2 .
To determine whether the secreted factor(s) were truly antiviral, we allowed the same culture supernatants to stimulate Huh7.5 cells for 8 h, at which time we infected the cells with VSV. We chose VSV for these studies because its ability to replicate is highly sensitive to the actions of interferons. Compared to supernatants collected from uninfected MEFs, culture supernatants from reovirus-infected MAVS-pex or MAVS-mito MEFs restricted the replication of VSV by 100-1,000-fold ( Fig. 1b) . As expected from the lack of STAT1 phosphorylation, culture supernatants from MAVS-cyto cells exhibited minimal antiviral activity. These results indicate that MAVS signaling from either mitochondria or peroxisomes induces secretion of antiviral activities that activate STAT1.
To determine whether STAT1 is required for antiviral responses induced from peroxisomes, we treated MAVS-pex MEFs with the small-molecule inhibitor of STAT1, fludarabine 13 . In response to reovirus infection, protein expression of the well-characterized ISG Rsad2 (also known as viperin) was blocked by fludarabine ( Fig. 1c) . Small interfering (si)RNA-mediated knockdown of STAT1 also revealed a requirement for this transcription factor in the ability of MAVS-pex to induce expression of viperin ( Fig. 1d and Supplementary Fig. 1a ). STAT1 activation is classically governed by Jak kinases 14 . To determine whether Jak signaling was also required for the antiviral responses activated from peroxisomes, we used the pan-Jak inhibitor pyridone 6 and the Jak2 inhibitors AG490 and 1,2,3,4,5,6-hexabromocyclohexane (HBC) 15, 16 . All these inhibitors blocked the induction of viperin in response to reovirus in MAVSpex MEFs (Fig. 1c) . Small interfering (si)RNA-mediated knockdown of Jak1 or Jak2 also revealed a requirement for these kinases in the ability of MAVS-pex to induce expression of viperin mRNA ( Fig. 1e and Supplementary Fig. 1b) . Moreover, the pan-Jak inhibitor pyridone 6 blocked the ability of MAVS-pex MEFs to control replication of VSV ( Fig. 1f) . These data establish that MAVS signaling from peroxisomes induces the secretion of Jak-STAT1-dependent activities and that these activities are required to create an antiviral cellular state. npg A r t i c l e s RLR-dependent expression and activities of type III interferons The experiments described above revealed that MAVS signaling from either peroxisomes or mitochondria induces secretion of antiviral factors. These factors must be cross-reactive between species because MEFs and Huh7 cells are of mouse and human origin, respectively. This point is notable because the cellular responses to type I interferons are species-specific 17 . For example, recombinant mouse IFN-β did not restrict VSV replication in human cells ( Fig. 1g) . Moreover, type I interferon signaling does not involve Jak2 (ref. 18 ), yet Jak2-specific inhibitors (AG490 and HBC) and siRNAs blocked the antiviral actions of this secreted factor ( Fig. 1c,e) . These experiments verify that signaling from peroxisomal MAVS does not induce secretion of type I interferon and indicate that the secreted factor of interest must be one that crosses species and exhibits antiviral activities that involve Jak2.
Although the antiviral activities of type I interferons cannot cross species, those of type III interferons can do so. For example, recombinant mouse type III interferon (also known as IFN-λ family or IL28-29, here referred to as IFN-λ2) induced phosphorylation of STAT1 ( Supplementary Fig. 1c ), activation of interferon-stimulated response element (ISRE; Supplementary Fig. 1d ) and protection from VSV infection in human cells ( Fig. 1g) . Mouse IFN-β exhibited none of these antiviral activities on human cells ( Fig. 1g and Supplementary Fig. 1c,d) , as expected 17, 19 . We found that recombinant human IFN-λ1 (but not IFN-β) induced phosphorylation of Jak2 ( Fig. 1h) , as reported 20 , and the ability of IFN-λ1 to activate ISRE-based reporter genes was blocked by a pan-Jak inhibitor and by the Jak2-specific inhibitor AG490 ( Fig. 1i) . Type I interferon signaling was not blocked by AG490 ( Fig. 1i) . Thus, type III interferons exhibit all the properties of the factor secreted after MAVS signaling from peroxisomes.
In contrast to our understanding of type I interferon gene expression, the mechanisms governing type III interferon expression are not understood 21 . Type III interferons are produced in response to many viruses, similar to type I interferons 11 . Little is known about what differentiates the signaling pathways that lead to type I versus type III interferon gene expression, and most studies have focused on the similarities between these two interferon systems 22, 23 . A major hurdle to understanding the regulation of type III interferon expression is that the most highly inducible family member in humans (IFN-λ1, also known as IL-29) is a pseudogene in mice 24 . Differences in expression (and function) of the type III interferon receptor have also been reported in human versus mouse livers 25 . Thus, although the type III interferon genes are functional in mice, they are less well-expressed and difficult to study experimentally 23, 26 . This difficulty in detecting type III interferon expression has hindered the use of mouse models to dissect the signaling pathways that control these antiviral genes. Thus, we used human cells to define the signaling pathways that regulate type III interferon expression, as humans encode a functional and highly inducible IFN-λ1 (ref. 11).
We tested the ability of a variety of primary cell types and laboratory cell lines to produce type I and type III interferons in response to a range of pathogens. We used mucosal epithelial and stromal cells of human origin because these cells express the highest levels of the type III interferon receptor 27 , and type III interferon signaling is required to control infections by mucosal pathogens 28 . We examined encounters between pathogens and the cell types they infect naturally (e.g., dengue virus in hepatocytes) and also used well-described activators of the RLR pathway, such as SeV. Infection of primary human hepatocytes, bronchial epithelial cells (BECs), keratinocytes, myoblasts, peripheral blood mononuclear cells (PBMCs) or monocytes with a range of viral pathogens resulted in the coincident expression of mRNA encoding IFN-λ1 (IFNL1) and IFN-β (IFNB1) ( Fig. 2a) .
In primary cells, basal levels of mRNA encoding IFN-λ were far lower than those for IFN-β. For this reason, here we did not present the inducible expression of interferon genes as a 'fold induction' value, but rather as compared to the expression of the housekeeping gene GAPDH. In T84 colonic epithelial cells, expression of type III interferon was induced at least as well as that of type I interferon in response to reovirus (Fig. 2b) . Huh7 hepatocytes also revealed that type III interferon expression coincides with type I interferon expression after infection with SeV ( Fig. 2c) or DenV (Fig. 2d) , the latter being a natural pathogen of hepatocytes 29 . To our surprise, Huh7 cells did not express any class of interferon genes in response to infection by the bacterial pathogen L. monocytogenes, but infection of Jeg3 trophoblasts, a natural target cell type of Listeria species infections, revealed a strong type III interferon response ( Fig. 2e) , consistent with our previous data 30, 31 . These data indicate that expression of type III interferons is a common feature of the antimicrobial responses that operate in human cells.
To understand the importance of type III interferons in the antiviral activities of human cells, we used neutralizing antibodies to the type I interferon receptor (IFNAR), the type III interferon receptor (IFNλR) or a combination of both in T84 intestinal epithelia. 5 h after infection with reovirus, neutralization of the IFNλR strongly reduced the ability of T84 cells to produce the ISGs RSAD2 (here referred to as viperin) or IFIT1 (Fig. 2f) . At that time, IFNAR-neutralizing antibodies were less effective than the IFNλR-neutralizing antibodies at influencing expression of ISGs. 24 h after infection, the effectiveness of the neutralizing antibodies was diminished. Nevertheless, the early disruption of ISG expression was functionally important, as type III interferon signaling was necessary to control reovirus mRNA expression: neutralization of IFNλR resulted in more reovirus transcripts as compared to neutralization of IFNAR ( Fig. 2g) . To complement these studies on receptor neutralization, we used inhibitors of the Jak-STAT pathway to determine their effect on ISG expression. Inhibitors of STAT1 (fludarabine) or Jak2 (AG490) blocked the induction of viperin mRNA (Supplementary Fig. 2a ) and other ISGs (Fig. 2h) to a similar extent, whereas the pan-Jak inhibitor pyridone 6 nearly abolished ISG expression ( Fig. 2h and Supplementary Fig. 2a ). As Jak2 inhibitors only block type III interferon signaling, these data suggest that type III interferon signaling controls antiviral gene expression, even when type I interferons are expressed.
Common and distinct regulators of IFN-b and IFN-l
In MEFs, the RLR pathway has been implicated in the control of type III interferon expression 22 . The aforementioned limitations of the mouse system to study type III interferon expression prompted us to reexamine this question. To investigate the pathway that drives type III interferon expression in human cells, we determined whether the RLR-MAVS pathway is required for production of IFNL1 mRNA in response to intracellular pathogens. We used Huh7 cells for these studies because they are easy to manipulate and are widely used to study host-pathogen interactions. We studied the involvement of RIG-I in type III interferon signaling using RIG-I-deficient Huh7.5. Infection with SeV revealed that RIG-I is required for production of IFNL1 as well as IFNB1 mRNA (Fig. 3a) . siRNA-mediated knockdown of MAVS ( Supplementary Fig. 2b ) also inhibited production of both interferon types in response to SeV (Fig. 3b ) and the natural pathogen of hepatocytes, DenV (Fig. 3c) 29 . To determine whether MAVS has a role in bacteria-mediated expression of type III interferon, we infected Jeg3 placental trophoblasts with npg A r t i c l e s L. monocytogenes. Knockdown experiments ( Supplementary Fig. 2c ) revealed that MAVS is required for the efficient expression of type III interferons in addition to type I interferons during infection by L. monocytogenes (Fig. 3d) . These collective data indicate that the RLR-MAVS pathway regulates the expression of both classes of interferons in various human cell types.
To identify proteins in the MAVS pathway that might selectively control type I or type III interferon expression, we focused on the most downstream components of the interferon cascade: transcription factors. IFN-β is induced by the combined action of a complex of transcription factors termed the enhanceosome 21 . This involves IRF3 and IRF7, NF-κB and AP-1, the latter of which is activated by MAP kinases (MAPK). The IFNL1 promoter contains binding sites for the transcription factors NF-κB and members of the interferon regulatory factor (IRF) family 21 . We used an siRNA-based approach to knock down IRF3 ( Supplementary Fig. 2d ) 32 . Consistent with the role of IRF3 as a critical regulator of antiviral immunity, depletion of IRF3 completely prevented the expression of both classes of interferon in response to SeV and DenV infection ( Fig. 3e,f) . siRNA-mediated knockdown of IRF7 marginally reduced both type I and III interferon induction to a similar extent ( Fig. 3g) , which suggested that this transcription factor has a limited role in the production of both cytokines. The IFNL1 promoter also includes four NF-κB binding sites. To test the requirement for NF-κB in production of IFN-λ1, we used two small-molecule inhibitors, pyrrolidinedithiocarbamate ammonium (PDTC) and Bay11 (Fig. 3h,i) . Either of these inhibitors blocked SeV-mediated production of IFNL1 and IFNB1 mRNA with comparable efficiency, which suggested that NF-κB is also required for the induction of IFN-λ1 in this system. Thus, several common regulatory factors exist that promote the expression of type I and type III interferon genes.
In addition to NF-κB and IRF proteins, the AP-1 transcription factor promotes the expression of IFN-β 21 . AP-1 is a large protein complex composed of dimers of members of the c-Jun, c-Fos and ATF families. These complexes are activated by MAPKs such as extracellular regulated kinase Erk, p38 or c-Jun N-terminal kinase Jnk. The role of AP-1 or MAPKs in production of type III interferons is unknown. We used small-molecule inhibitors of Jnk (SP600215), MEK and Erk (PD98059) or p38 (SB202190) on Huh7 hepatocytes to assess the role of each MAPK in interferon gene expression in response to SeV infection ( Fig. 4a) . Whereas p38, Jnk or MEK-Erk inhibition disrupted expression of IFNB1 mRNA to varying extents, only p38 inhibitors disrupted expression of IFNL1 mRNA (Fig. 4a) . Treatment with Jnk or MEK-Erk inhibitors did not interfere with expression of type III interferons (Fig. 4a) . siRNA-mediated knockdowns Erk family members confirmed their selective role in the expression of IFNB1 mRNA ( Fig. 4b and Supplementary Fig. 2e ). Results obtained with siRNA-mediated knockdown of p38 differed from the results obtained with inhibitors, and suggested a selective role for this MAPK family in expression of IFN-β ( Fig. 4c and Supplementary Fig. 2f ). These data indicate that each component of the enhanceosome is necessary for expression of IFNB1 but that a subset of enhanceosome components is sufficient for expression of IFNL1 mRNA. Thus, it stands to reason that distinct signaling pathways may exist that selectively promote expression of type III interferon genes without activating expression of type I interferons.
The above data revealed that some MAPKs are selectively needed for the expression of type I interferons. To determine whether factors exist that are selectively needed for expression of type III interferons, we considered the transcription factor IRF1. Although IRF1 is encoded by an ISG, it is present in a variety of cells before viral A r t i c l e s infection 33 (Supplementary Fig. 2g ). IRF1 had been the first IRF family member shown to bind the IFNB1 promoter 33 , suggesting an important role in regulating expression of this gene. However, later IRF1 had been demonstrated to be dispensable for expression of type I interferons during viral infections of Irf1-deficient MEFs or mice 34 . IRF1 was also implicated in type I interferon-independent antiviral responses 2,35 , perhaps via interactions with the IFNL1 promoter in the lung 36, 37 . We used siRNA-based approaches to define the role of IRF1 in the regulation of interferon expression. We carried out RNA interference-based knockdown of IRF1 in Huh7 cells ( Supplementary  Fig. 2g ), which we subsequently infected with SeV. Knockdown of IRF1 had no effect on IFNB1 mRNA levels 6 h after infection but completely inhibited expression of IFNL1 mRNA after SeV infection (Fig. 4d) . These data reveal an important role for IRF1 in controlling expression of type III interferons. At late time points of infection (24 h), IRF1 knockdown reduced the production of both classes of interferons ( Fig. 4d) . However, at this late time point, the synergistic effects of secreted interferons and RLR signaling may complicate our ability to explain this observation. A useful means to address the role of IRF1 in interferon expression would be to study a virus that prevents signaling induced by secreted interferons. DenV is useful in this regard, as this virus blocks signaling downstream of interferon receptor ligation 38 . Although IRF1 was not required for expression of IFNB1 in response to DenV, it promoted expression of IFNL1 mRNA (Fig. 4e) . As both IRF1 and IRF3 regulate IFNL1 mRNA expression, we considered the possibility that IRF1 might somehow regulate the activation of IRF3. We assessed this by determining whether IRF3 can be phosphorylated in Huh7 cells that have been depleted of IRF1 through the use of siRNAs. We found that SeV infection induced the phosphorylation of IRF3 within 3 h of infection, even when IRF1 was knocked down (Fig. 4f) . This result suggests that IRF1 and IRF3 are activated independently of each other but act together to promote expression of IFNL1 mRNA. These data reveal an important role for IRF1 in the control of expression of type III interferons induced by multiple viral pathogens, especially during the primary phase of infection. Thus, IRF1 can be considered a counter to Erk, in that it is selectively required for expression of type III interferons, whereas Erk is selectively required for expression of type I interferons. Taken together, these data demonstrate that many common regulators control type I and type III interferon expression, but these genes can also be expressed independently of each other.
Peroxisomal MAVS induces selective expression of IFN-l
We showed above that peroxisomal MAVS induces secretion of a factor that can cross species to activate a Jak-STAT pathway that is regulated by Jak2. We also showed that human type III interferon signaling is regulated by Jak2, but type I interferon signaling is not. These results suggest that peroxisomal MAVS preferentially induces type III interferons. To test this prediction directly, we needed a cell type that expresses high levels of type III interferons and expresses MAVS selectively on peroxisomes. Therefore we engineered Huh7 cells to stably express the relocalized MAVS transgenes 2 described above that encode either wild-type MAVS or variants that are localized specifically to mitochondria, peroxisomes or the cytosol. The resulting cell populations were sorted by flow cytometry to select clones that express comparable amounts of the transgenes ( Supplementary  Fig. 2h ). Then we depleted the endogenous MAVS mRNA by using siRNAs that target the 5′ untranslated region of the MAVS mRNA, which resulted in cell lines that preferentially expressed the transgene of interest. To test whether peroxisomal MAVS in human cells could induce STAT1 phosphorylation in a Jak2-dependent manner, we treated cells with the pan-Jak inhibitor pyridone 6 and the Jak2 inhibitors AG490 and HBC. Infection with SeV induced phosphorylation of STAT1 in the cells expressing the wild-type MAVS, 
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A r t i c l e s MAVS-pex or MAVS-mito (Fig. 5a) . This response was blocked by all the inhibitors listed above, which indicated that MAVS-pex Huh7 cells respond similarly to MAVS-pex MEFs and can be used to test whether MAVS localized on peroxisomes induces expression of type III interferons. We noted that infection with SeV induced a weak phosphorylated STAT1 signal in cells with the allele encoding the signaling-deficient MAVS-cyto, probably resulting from incomplete knockdown of MAVS (Fig. 5a) . This observation highlights some limitations of this system but also the importance of this negative control in subsequent experiments. Indeed, we found some residual SeV-mediated interferon production in cells expressing MAVS-cyto ( Fig. 5b) . Therefore, interferon levels produced by the MAVS-cyto line were considered to be the 'background' expression, above which signaling was considered significant (one-way ANOVA P < 0.05). In response to infection with SeV, only cells with alleles encoding wildtype MAVS and MAVS-mito induced expression of IFNB1 mRNA, whereas MAVS-pex cells did not (Fig. 5b) . However, MAVS-pex cells induced the expression of IFNL1 mRNA (Fig. 5b) . Infection with DenV ( Fig. 5c,d ) yielded comparable results: peroxisomal MAVS induced IFNL1 but not IFNB1 mRNA, whereas wild-type and mitochondrial MAVS induced both. The magnitude and kinetics of each transcriptional response differed greatly between viral infections, a result that likely reflects some aspect of the diverse lifecycles of the pathogens examined.
To determine whether the ability of peroxisomal MAVS to induce expression of type III interferon extended to bacterial infections, we returned to L. monocytogenes and Jeg3 cells, in which MAVS transgenes were overexpressed (Supplementary Fig. 2i ). As infection with this bacterium disrupts mitochondria 39 , and mitochondrial disruption hinders RLR signaling from this organelle 40 , we hypothesized that peroxisomal MAVS might have a dominant role in the interferon response to L. monocytogenes infection. Indeed, in Jeg3 trophoblasts, where the interferon response to L. monocytogenes is MAVS-dependent ( Fig. 3d) , expression of peroxisomal MAVS strongly potentiated the ability of these cells to express IFNL1, although IFNB1 mRNA was also induced (Fig. 5e) . Overexpression of MAVS-mito did not induce the expression of any class of interferon above those induced by MAVS-cyto (Fig. 5e) . The observation that peroxisomal MAVS contributes to type I interferon expression during L. monocytogenes infection, but not during viral infection, is noteworthy. One potential explanation for this finding is based on the fact that in addition to RLRs, L. monocytogenes activates other pattern recognition receptors in the cytosol 41 . The transcription factors activated by RLRs and other pattern recognition receptors may synergize to create a transcriptional profile distinct from that seen for viruses that only activate RLRs.
Although the above experiments revealed the ability of peroxisomal MAVS to induce the selective expression of type III interferons, the magnitude of interferon and ISG expression was less than that observed for cells expressing wild-type MAVS. This result is consistent with prior work showing that MAVS signaling from peroxisomes and mitochondria (coordinated around the mitochondria-associated membrane) synergize to induce maximal expression of antiviral genes 2,9 . To determine whether the amount of interferons released by cells expressing MAVS-pex was functional, we asked whether culture supernatants from infected cells could confer an antiviral state. We transferred culture supernatants from infected MAVS-pex Huh7 cells onto Huh7.5 cells and assessed the ability of VSV to replicate. In response to either SeV or DenV (Fig. 5f) , peroxisomal MAVS induced the release of functional amounts of interferons that blocked VSV replication. These data establish peroxisomes as an organelle that can induce selective expression of type III interferons upon activation of the RLR-MAVS pathway.
To determine whether the pathway leading from peroxisomal MAVS was similar to that observed in wild-type cells, we assessed the effect of MAPK inhibitors on virus-induced gene expression. Whereas wild-type MAVS signaling was inhibited by inhibitors of Jnk (SP600125), MEK and Erk (PD98059) and p38 (SB202190), production of viperin mRNA in Huh7 cells expressing MAVS-pex was unaffected (Fig. 5g) . siRNA-mediated knockdown of Erk in MEFs also abolished the ability of SeV to induce phosphorylation of STAT1 upon signaling by wild-type MAVS, but not MAVS-pex ( Fig. 5h and  Supplementary Fig. 2j) , which confirmed that this MAPK does not control type III interferon responses. A r t i c l e s Peroxisome abundance controls the production of IFN-l Although the type I interferon system appears to be important in most mammalian cell types, the type III interferons appear to be most critical at mucosal surfaces, in particular in epithelial cells of the intestine, liver and lung. These observations suggest that epithelial cells might exhibit unusual cell biological characteristics that enhance the type III interferon system. To address this possibility, we turned our attention to human T84 intestinal epithelial cells, which can be differentiated into a polarized monolayer of cells that exhibit many functional and morphological properties of primary epithelia. Differentiation of T84 cells occurs over the course of several days, which allows us to determine whether the process of epithelial differentiation into a polarized monolayer would influence the RLR-MAVS pathway. As expected, the transepithelial resistance of the T84 cell monolayer increased over time, which is a functional indication of epithelial polarization (Fig. 6a) . As T84 intestinal epithelial cells polarized, the abundance of peroxisomes increased, whereas that of mitochondria remained unchanged ( Fig. 6b and Supplementary Fig. 3) . This increase in abundance of peroxisomes correlated with an increase in expression of the gene encoding Pex11β (PEX11B), which is a master regulator of peroxisome proliferation (Fig. 6c) . To determine whether the change in the abundance of peroxisomes relative to that of mitochondria influences RLR-MAVS signaling events, we infected the T84 cells with the intestinal pathogen reovirus at various times during the differentiation process. At any day of differentiation, the T84 cells responded equally well to reovirus and produced roughly equal amounts of IFNB1 mRNA (Fig. 6d) . In contrast, the magnitude of the IFN-λ response (IFNL1 mRNA levels) increased over time (Fig. 6d,e) , which correlated with an increase in PEX11B mRNA, peroxisome abundance and transepithelial resistance. These data reveal that as epithelial cells differentiate into a polarized monolayer, they shift from a dominant type I interferon to type III interferon response, which may be caused by an increase in peroxisome abundance.
To determine whether increasing abundance of peroxisomes was sufficient to influence the RLR-MAVS pathways, we induced the proliferation of peroxisomes in Huh7 cells by overexpression of Pex11β. As expected 42 , we observed a marked increase of Pex14-positive peroxisomes in Pex11β-expressing cells (Fig. 6f) . This increase in the abundance of peroxisomes correlated with an increase in production of IFNL1 mRNA in response to SeV infection, but expression of IFNB1 mRNA was unaffected (Fig. 6g) . These data therefore provide a direct link between the abundance of peroxisomes and the quality of the interferon response induced by the RLR-MAVS pathway.
Finally, we determined whether the endogenous MAVS protein on peroxisomes was sufficient to induce type III interferons. Disruption of mitochondrial function with the protonophore carbonyl cyanide m-chlorophenylhydrazone (CCCP) has been used to reveal the importance of mitochondrial integrity for RLR signaling 40 . Notably, 
A r t i c l e s peroxisome functions are unaffected by CCCP 43 . We reasoned that if endogenous peroxisome-localized MAVS functioned to control expression of type III interferons, then CCCP-treated cells may retain the ability to induce these interferons. Alternatively, if mitochondria are the sole subcellular site of RLR-MAVS signaling, then treatment with CCCP should block expression of all RLR-induced genes to a similar extent. To address this possibility, we used primary human keratinocytes because they produce and respond to type III interferons and because they tolerate treatment with CCCP. Over the course of the 3-d experiments, keratinocytes remained viable and robust. Treatment with CCCP eradicated the functional mitochondrial pool in these cells, as assessed by mitotracker staining (Fig. 6h) . Under these conditions, SeV-mediated production of IFNB1 mRNA was completely inhibited (Fig. 6i) , similar to what has been observed 40 . By contrast, expression of the ISG viperin and IFNL1 was enhanced in the presence of CCCP (Fig. 6i) . These data indicate that even in primary cells, the endogenous RLR signaling pathway can operate in the absence of functional mitochondria, and that this pathway can be 'rewired' to produce only type III interferons, likely from peroxisomes.
'Zellweger cells' implicate peroxisomes in RLR signaling
The studies described above suggested that RLR signaling via MAVS can occur in cells lacking functional mitochondria, thus raising the question of how MAVS populates peroxisomes and how these organelles are functionally interconnected. To address these questions, we used cells derived from human patients with Zellweger syndrome, which is a peroxisome biogenesis disorder. These patients have defective peroxisomes and suffer from various developmental abnormalities, which often results in death early in life 44 . Death can be associated with infection (usually pneumonia) and patients display elevated cytokine levels, particularly in the brain 45 . The immunological basis for these observations is unclear, as cells from patients with Zellweger disease (here referred to as 'Zellweger cells') have not been thoroughly examined for alterations in innate immune signaling pathways. Zellweger cells that lack a functional PEX14 gene contain peroxisomal membranes that stain for the membrane protein PMP70, but these organelles lack all cargo that is normally present in the lumen, such as catalase 44 (Supplementary Fig. 4 ). We found that cells lacking Pex14 retain MAVS on their limiting membrane ( Supplementary  Fig. 5 ), suggesting that MAVS does not require Pex14 for its ability to localize to peroxisomes. Thus, MAVS can be categorized as a peroxisomal membrane protein that is targeted to these organelles by Pex14-independent means.
Unlike in the case with Pex14 deficiency, patients with Zellweger disease that lack functional Pex16 or Pex19 lack physically distinct peroxisomes 46 (Supplementary Fig. 4 ). In these cells, peroxisomal membrane proteins can be mistargeted to mitochondria 47, 48 . Thus, Pex19-deficient or Pex16-deficient cells contain mitochondria that display both peroxisomal and mitochondrial proteins on their limiting membranes. These observations are intriguing when considering recent work which suggests that physical interactions between mitochondria and peroxisomes lead to an enhanced RLR-dependent response to viral infection 9 . Although the molecular basis for these observations remains unclear, it seems reasonable that membrane proteins on each organelle would interact to promote more efficient MAVS-dependent cellular responses. For this reason, we wondered if Zellweger cells lacking Pex19, which contain peroxisomal and mitochondrial proteins on the same organelle, might display an aberrant response to viral infection. To address this possibility, we infected Pex19-deficient cells or Pex19-deficient cells stably expressing Pex19 with mammalian reovirus. Then we examined the cells 9 h and 2,000 A r t i c l e s immune response, as apparent from Gene Ontology term analysis (Supplementary Fig. 6a ). Global transcriptome analysis revealed that Pex19-deficient cells displayed a higher antiviral response at all time points examined (Supplementary Fig. 6b-d) . Of note, of the 20 genes that are most highly upregulated in Pex19-deficient cells compared to reconstituted cells, most are ISGs (Supplementary Fig. 6d) . These data suggest that the presence of mitochondria containing peroxisomal proteins promotes greater RLR-dependent responses. These studies underscore the important role of peroxisomes in regulating RLR signaling, and provide to our knowledge the first insight into immunological consequences of Pex19 deficiency in human disease.
DISCUSSION
We demonstrated that RLRs can signal via MAVS from peroxisomes to drive the synthesis of type III interferons. We revealed that the RLR pathway can induce expression of different classes of interferon genes and that the decision of which genes to induce is determined by the location in the cell where RLR signaling is initiated. Our results therefore highlight how the microenvironments of different cell types can influence the activity of a given signaling pathway. First, using both direct (mRNA quantification) and indirect (functional assays) approaches, we found that the RLR network can induce the expression of type I and type III interferons in response to infections with diverse intracellular pathogens, in seven primary human cell types and three different cell lines. Second, the ability of type III interferons to be expressed was directly controlled by the differentiation state of intestinal epithelial cells and occured as a function of the abundance of peroxisomes. Third, depletion of mitochondria in primary human keratinocytes did not inactivate the RLR pathway but shifted the RLR pathway to be a primary producer of type III interferons. These data identify type III interferons as a major component of the RLR pathway emanating from peroxisomes and suggest that cell type-specific expression of classes of interferons can be achieved by altering the abundance of peroxisomes or mitochondria in a given cell population. It has been generally considered that expression of type I and type III interferons is coregulated and induced by a common (unknown) signaling pathway. Our work to define the means by which peroxisomal MAVS can induce antiviral gene expression revealed that these interferon classes can be induced differentially. We identified the existence of complementary but distinct regulators that control expression of type I and type III interferons. We found that the transcription factor IRF1 is necessary for expression of type III interferons and Erk MAPKs are necessary for expression of type I interferons. These data suggest a plausible model whereby expression of type III interferons from peroxisomes can be achieved without the expression of type I interferons. We suggest that the MAVS pathway from peroxisomes does not activate Erk, but does activate NF-κB and IRF3. This partial activation of the components of the classically defined enhanceosome would preclude expression of IFNB1 but would permit the expression of IFNL1. When considered in this context, it would be expected that pathogens that activate multiple pattern recognition receptors may create a means of 'complementing' the defect in MAPK signaling and allow the peroxisomal pathway to induce expression of type I interferons. This idea may therefore explain why peroxisomal MAVS induces the expression of type I and type III interferons during Listeria infections, as these bacteria also strongly activate MAPK family members.
Although our studies highlight how type III interferons can be induced selectively from peroxisomes in epithelial cells, they also raise the question of why these different interferon families exist.
One would expect that type III interferons would induce different cellular responses than their type I counterparts. However, analysis of gene expression indicated a largely overlapping set of genes that are induced by the type I and type III interferon receptors. Why then is the expression of the type III interferon receptor selectively detected on mucosal epithelial cells, and why is the ability of intestinal epithelia to express type III interferons dependent on the degree of cell polarization? We propose that in addition to transcriptional responses, the RLR pathway (via type III interferons) may elicit cellular responses that are more compatible with the specific homeostatic functions of epithelia than RLR-induced type I interferons. Possible examples of such cellular responses include activities that may influence cell-cell communication, viability or metabolism. This prediction may explain why type III interferon expression is linked to the polarization of T84 intestinal epithelial cells, and may explain the benefit of allowing RLR signaling to occur from multiple organelles. By separating the subcellular sites of RLR signaling and allowing different cellular responses to occur from these different sites, the RLR network can be modified to emphasize or deemphasize an organelle-specific response to fit the homeostatic needs of any given type of cell. The findings presented in this study support these ideas and provide a mandate for future work on the cell type-specific functions of the innate immune signaling networks in mammals.
METhODS
Methods and any associated references are available in the online version of the paper.
